View Cart  

Sponsors Forced to Repeat Studies in Light of Suspect Cetero Data

Some generic-drug makers who used the discredited contract research organization (CRO) Cetero Research will need to reanalyze or repeat studies, while others will need to conduct an independent third-party data audit, the FDA told drugmakers.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00